Britain and America have forged a major bilateral deal that will ensure no tariffs on UK medicine exports entering the US market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on drugs through the public health system. This move ensures that import taxes on these key products will stay at zero for a period of the next three years.
This development is in response to earlier warnings to dramatically increase import taxes on branded drug products, with potential rates mentioned reaching 100%.
"This arrangement between the UK reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to U.S.–U.K. drug exports," a release declared.
Commercial Significance
Drugs represent one of the the United Kingdom's largest export categories to the United States, which is easily the biggest market for major British pharmaceutical firms.
Export figures indicate that in the year to the end of last September, the UK sold pharmaceutical products totaling £11.1bn to the US. This figure represented a significant portion of all goods exports in that span.
"This guarantee safeguards work, boosts capital expenditure and sets the stage for the UK to establish itself as a worldwide center for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several specific commitments from the UK:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to control costs will be capped at 15%. In the past, repayments were more than 20%.
Recent Tensions
The deal comes amid a long-running row between the sector and the ministers over medicine costs and NHS adoption.
These tensions were intensified by arguments that American consumers were charged significantly more for the same drugs than people in the other developed nations.
Recently, several large drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward American operations.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had declined as a share of its total funding over the last ten years.
